Published Date: 08 Mar 2023
Interventions to improve clinical practice increased the odds that people with type 2 diabetes and heart disease were prescribed the drugs recommended in our study by more than 100%.
Read Full NewsA randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.
A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
1.
Novel Agent for Chronic GVHD Wins FDA Approval
2.
In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events
3.
Including Bereavement in the Care Continuum.
4.
Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer
5.
Taking Charge of Your Cancer Journey.
1.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
2.
A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
3.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
4.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
5.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XII
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation